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macular degeneration (AMD). METHODS: A systematic review of literature was
conducted. The bibliographic search covered the period between January 1996 and
January 2011. The search was run on MEDLINE, EMBASE, Cochrane library, INAHTA
and ECRI. The criteria employed to select the papers were: population (AMD pa-
tients), treatment (Ranibizumab or Bevacizumab), comparison (placebo or other
active treatments). To assess the efficacy, it was decided to include systematic
reviews and randomised clinical trials (RCT). For the safety, it was considered any
type of study. RESULTS: The bibliographical search retrieved 731 references of
articles and 51 papers were finally included: 4 were controlled clinical trials: two on
Ranibizumab and two on Bevacizumab. Efficacy: Ranibizumab and Bevacizumab,
as compared to placebo as to Verteporfin, gets results in terms of AMD stabilization
(between 0 and 1.2% of severe visual losses as opposed to 13-16% in the control
groups), in terms of reduction in the lesion size and it even achieves improvement
in visual acuity in some cases. Safety: The adverse effects (of any magnitude) were
more frequent in the groups treated with Ranibizumab and Bevacizumab than in
the control groups (placebo and Verteporfin). The data’s synthesis showed adverse
effects similar in both drugs. Economic Evaluation: Drug costs for 1 year of treat-
ment were estimated as 2.330€ for Ranibizumab and 53€ for Bevacizumab.
CONCLUSIONS: : Both drugs provide startling benefits in the treatment of age-
related macular degeneration (AMD). Cost effectiveness analysis of bevacizumab
makes this intervention highly cost effective versus ranibizumab. The price of
ranibizumab would have to be drastically reduced for it to be cost effective. Public
pressure may be the most potent weapon in persuading Genentech to license
bevacizumab for AMD.
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OBJECTIVES:To characterize the economic and societal burden of Diabetic Macular
Edema (DME) in Canada. METHODS: Patients with clinically significant macular
edema (CSME) were enrolled by ophthalmologists or retinal specialists across Can-
ada. Patients are followed over a 6-month period to combine prospective data
collected during monthly telephone interviews and at sites at months 0, 3 and 6.
Visual acuity (VA) is measured and DME-related health care resource information
is collected. Patient health-related quality of life is measured using the National
Eye Institute Visual Functioning Questionnaire (NEI VFQ-25), and the EuroQol Five
Dimensions (EQ-5D). The 3-month results are available and presented here.
RESULTS: A total of 145 patients [mean age 63.8 years (range: 30-86 yrs); 52% male;
81% Type 2 diabetes; mean duration of diabetes 18 years (range: 1-62 yrs); 72%
bilateral CSME] were enrolled from 17 sites across 6 provinces in Canada. At base-
line, the mean VA was 20/60 (range: 20/20-20/800) across all eyes diagnosed with
CSME (249 eyes). Sixty-eight percent of patients had VA severity in the worse seeing
eye of normal/mild vision loss (VA 20/10 to  20/80), 19% moderate vision loss (VA
 20/80 to  20/200), and 13% severe vision loss/nearly blind (VA  20/200). At
month 3, the mean NEI VFQ-25 composite score was 79.9, the mean EQ-5D utility
score was 0.79, and the EQ visual analogue scale score was 70.6. The average
3-month DME-related cost per patient was $1,487 across all patients (95% confi-
dence interval: $1,164 to $1,810). The cost was $1,390 for patients with normal/mild
vision loss, $1,831 for patients with moderate vision loss, and $1,467 for patients
with severe vision loss/nearly blind. CONCLUSIONS: DME is associated with limi-
tations in functional ability and quality of life. In addition, the DME-related cost is
substantial to the Canadian health care system.
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OBJECTIVES: Psoriasis, an immune mediated disorder with skin manifestations
and comorbidities, has high resource requirement. Specifically, diabetes is highly
prevalent in psoriasis patients and may represent a substantial incremental eco-
nomic burden. This retrospective study aimed to estimate the incremental costs of
psoriasis and diabetes in psoriasis patients. METHODS: Adult patients with psori-
asis (i.e., 2 psoriasis diagnoses ICD-9 codes:696.1x) were selected from a large US
administrative claims database. Psoriasis-free controls were matched with the
psoriasis sample by age and gender in a 1:1 ratio. All patients were followed for one
year to assess their healthcare costs. Incremental total healthcare costs (USD 2010)
associated with psoriasis and diabetes in a psoriasis population, measured from a
third-party payer perspective, were estimated using regression models controlling
for age and gender. RESULTS: A total of 106,128 matched pairs were studied.
Among psoriasis patients, 16% had diabetes compared to 13% of the psoriasis-free
controls (p.001). Psoriasis was associated with a $4,523 adjusted increment total
health care costs among patients without diabetes ($10,017 vs. $5,539; p.001),
compared to $5,984 among patients with diabetes ($19,536 vs. $13,589; p.001). In
the psoriasis population, diabetes presented a $8,337 adjusted incremental cost
compared to the psoriasis patients without diabetes ($19,536 vs. $10,017; p.001).
This was $1,460 more than the adjusted incremental costs from diabetes among
controls without psoriasis (p.001), representing an interaction of psoriasis and
diabetes conditions, which significantly increases the health care costs.
CONCLUSIONS: Both psoriasis and diabetes are expensive conditions to treat. The
incremental economic burden of patients having both diseases is significantly
higher than each condition individually, potentially due to the complexity of man-
aging both conditions at the same time.
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OBJECTIVES: Analyse the burden of chronic hand eczema (CHE) patients with ep-
isodes of severe disease preceding the availability of the first approved systemic
treatment in 2008. METHODS: In this cost-of-illness study, 310 patients with CHE
refractory to topical steroids in Germany were analyzed (patients with coverage by
statutory (GKV) or occupational health insurances (BG)). The cross-sectional survey
instrument collected data on patient characteristics, clinical status (i.e. max. se-
verity in past year and at inclusion) and resource use. Only patients with severe
disease (photographic guide) in the year preceding this study were selected for this
analysis. The following aspects were investigated: resource use, costs, clinical sta-
tus (at inclusion) and quality of life (DLQI). RESULTS:A total of 161 (52 %) of the CHE
patients had severe CHE during the last 12 months (similar fractions in both insur-
ances categories) and 74 % of these patients reported a moderate/severe disease
status (Physician global assessment (PGA)) at inclusion. The average DLQI score at
inclusion was 8.1 (moderate effect on patient’s life). Approximately half of the
patients received only topical treatments, while the remaining patients received a
combination of topical therapies with UV-therapy (68 %) and/or systemic therapies
(36%). The yearly health care costs of these patients were €2221 (GKV patients) and
€3961 (BG). CONCLUSIONS: Among these CHE patients refractory to topical corti-
costeroids, half of the patients had severe disease during the year prior to the
survey. Despite the extensive usage of health care resources (incl. UV-therapy,
off-label systemic therapies and hospitalization), the CHE disease severity state did
not change considerably for most patients. It remains to be seen whether the
availability of the first approved systemic treatment (alitretinoin) for severe CHE
will change the dynamics seen in this disease and therefore, further prospective
studies are warranted to clarify this aspect.
PSS15
BURDEN OF CHRONIC TINNITUS IN HUNGARY
Kiss Z
United BioSource Corporation, London, London, UK
OBJECTIVES: Tinnitus has a major effect on quality of life when it occurs for a
longer period of time. It is a conservative estimate that 10% of the general popula-
tion experiences spontaneous prolonged tinnitus. The aim of this study is to esti-
mate the burden and cost of tinnitus in Hungary from three different perspectives,
as no publicly available cost or burden of illness study has been found in this field.
The objective is to fill this gap in the Hungarian setting. METHODS: The present
study identified both the costs that are made and the resources that are lost in the
form of direct medical and nonmedical costs and indirect costs associated with
tinnitus. An expert panel based estimate was used to identify probabilities for the
different paths and resource use, due to lack of information in the literature. Direct
medical costs were observed from the National Health Insurer’s (NHI) database,
while the indirect costs were estimated according to the human capital approach.
The cost estimates were based on a model structured by a decision tree. RESULTS:
An annual cost of 91,891Ft (€ 328) has been estimated for a newly diagnosed tinni-
tus patient. The average treatment cost borne by the NHI is 6,363Ft (€ 23), while a
37,534Ft (€ 134) cost was assigned to the diagnosis of a typical patient attending an
ENT specialist. Indirect cost consist of sick leave cost which is 861Ft (€3.1), 3,118Ft
(€11) and 8,743Ft (€31) in the different cost categories of NHI costs, out of pocket
costs and societal costs, respectively. CONCLUSIONS: From the societal perspec-
tive, the annual cost of tinnitus amounted for 0.01% of the Hungarian GDP in 2009
which is almost evenly borne by the NHI and the population with tinnitus. There is
little information in either the Hungarian or the international literature to validate
the model against.
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OBJECTIVES: Literature concerning epidemiology of blindness and with these dis-
ease patterns associated economic consequences is very rare. The aim of this
analysis was to close this research deficit for Austria by evaluating the whole
economic impact of blindness for the Austrian society using the incidence
approach. METHODS: A model that captures all causes of blindness (AMD, glau-
coma, diabetic retinopathy, cataract, and other causes) was developed. We differ-
entiated between age groups as well. Cost of illness comprises direct medical cost
(treatment, consultations, devices, cost of depression, hip fractures etc.) and direct
non-medical cost (adaption of housing facilities). Indirect cost are allowance for
nursing care, cost for assisted living and productivity loss. The analysis was per-
formed from a society’s perspective. Cost are calculated from onset of blindness
until death (reduced life expectancy due to blindness) (dicount rate 5%). The anal-
ysis was performed according to the Austrian Guidelines for Healtheconomic
evaluations. RESULTS: In Austria every year 1160 (Incidence) people go blind. Total
cost (direct and indirect) of blindness over all age groups value €105.71 Mio. (incl.
allowance for nursing care) over lifetime. Direct cost account for 3% of total cost
(€3.61 Mio.) and indirect cost for 97% (€102.09 Mio.). Highest cost of blindness over
lifetime can be found within the groups ,opticusatrophy‘ (18-39-year-old-patients)
with 11.77 Mio., diabetic retinopathy‘ (60-79-year-old-patients) with cost of €7.02
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